Fig. 1

Study design. ^aEligibility period determined between a minimum of 30 days and a maximum of 40 days. ^bPatients randomized to galcanezumab 120 mg received a loading dose of 240 mg at the first injection only (Visit 3). ^cTelephone visits. dAt Visit 7, patients randomized to placebo who entered the open-label extension received galcanezumab at a loading dose of 240 mg, while patients randomized to galcanezumab 120 mg continued treatment at the 120 mg dose. SP, study period; X indicates when dosing occurred